A drug pricing policy in japan and the us is reportedly delaying the sales of new drugs. There are concerns about the impact of pricing rules on pharmaceutical innovation and access to new drugs, with some companies warning that us drug pricing could affect launches in other countries. The situation is complex, with various factors at play, including antitrust cases and potential revisions to japan's drug price revision system.